Prometheus Biosciences Announces Appointment of Mark Stenhouse as Chief Operating Officer
News provided by
Share this article
Share this article
SAN DIEGO, March 4, 2021 /PRNewswire/ Prometheus Biosciences, Inc. ( Prometheus ), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the appointment of commercial veteran Mark Stenhouse as Chief Operating Officer. Mark s leadership and deep experience with GI diagnostics and therapeutics make him a great fit for Chief Operating Officer, which is a key role as we accelerate our growth, said Mark McKenna, President and CEO of Prometheus. His thirty years of biopharma industry experience, and building and leading successful teams, will strengthen our leadership team as we seek to revolutionize the treatment of IBD with a precision medicine a
Share this article
Share this article
SAN DIEGO, Feb. 16, 2021 /PRNewswire/ Prometheus Biosciences, Inc. ( Prometheus ), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the appointments of Judith L. Swain, MD and Helen C. Adams to its board of directors. Ms. Adams will assume the position of Chair of the Audit Committee. We re thrilled to have Judith and Helen join our Board of Directors, who bring significant clinical medicine and financial expertise that will be important as we advance our pipeline to people living with IBD, said Mark McKenna, President and CEO of Prometheus. Judith is a distinguished physician scientist and veteran scientific advisory board member with an international perspective on drug development. Helen is an outstanding financial professional and exper
Common gut inflammation linked to COVID-19, study finds
Credit: CC0 Public Domain
In a new study, researchers found An enzyme that helps COVID-19 (coronavirus) infect the body also plays a role in inflammation and patient outcomes in inflammatory bowel disease (IBD).
The findings raise the possibility that anti-inflammatory drug therapies for IBD may aid recovery from coronavirus.
The research was conducted by a team at Cedars-Sinai and elsewhere.
In the study, the team focused on angiotensin-converting enzyme 2 (ACE2), which normally plays a crucial health role by activating a hormone that helps regulate blood pressure.
But in COVID-19 infections, the SARS-CoV-2 virus binds to ACE2 and uses it to invade and infect cells, “hijacking” them to spread the virus.
Published: Dec 15, 2020
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ Prometheus Biosciences, Inc. ( Prometheus ), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the diagnosis and treatment of inflammatory bowel disease (IBD), today announced FDA acceptance of its Investigational New Drug Application (IND) for PRA023 and that dosing has commenced in a Phase 1a clinical study in normal healthy volunteers. PRA023, the company s lead product candidate, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A). TL1A is a validated clinical target that is being developed for the treatment of the two most common forms of IBD, ulcerative colitis (UC) and Crohn s disease (CD). Prometheus recently completed a $130M financing to advance novel precision medicine approaches in IBD.